Defence Therapeutics Inc
Canadian Securities Exchange:DTCView on Grey Market

  • LAST PRICE
    0.5200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.5100/ 44
  • Ask / Lots
    0.5500/ 1
  • Open / Previous Close
    0.5300 / 0.5200
  • Day Range
    0.5200
    0.5300
  • 52 Week Range
    0.4800
    2.8500
  • Volume
    250

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 14, 2024

      Show headlines and story abstract

    • 7:31PM ET on Thursday Nov 14, 2024 by Newsfile
      Companies Mentioned: DTCFF

      Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, announces that it offers new unsecured convertible debentures (the "New Debentures") for aggregate gross proceeds of up to CAD$1,570,000 (the "Offering") in consideration for the settlement of the principal amounts owing to holders of the Previous Debentures (as defined below) (the "Outstanding Debt").

    • 7:31PM ET on Thursday Nov 14, 2024 by Dow Jones
      Companies Mentioned: DTC

      Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, announces that it offers new unsecured convertible debentures (the "New Debentures") for aggregate gross proceeds of up to CAD$1,570,000 (the "Offering") in consideration for the settlement of the principal amounts owing to holders of the Previous Debentures (as defined below) (the "Outstanding Debt").

  • Nov 13, 2024

  • Nov 4, 2024

      Show headlines and story abstract

    • 6:17PM ET on Monday Nov 04, 2024 by Dow Jones
      Companies Mentioned: DTC

      Vancouver, British Columbia--(Newsfile Corp. - November 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that it has received a 30-day extension approval from Canadian Securities Exchange to extend the closing for the balance of its previously announced non-brokered private placement of units of the Company (the "Units") at a price of $0.50 per Unit (the "Offering"). Under the first tranche of the Offering which closed on October 30, 2024, the Company sold 1,550,000 Units for gross proceeds of $775,000.

Peers Headlines